The Menopause Digest 06/09 - 06/15

Welcome to The Menopause Digest.

The field moves fast. Too fast for most of us to track every breakthrough, every protocol update, every researcher’s latest findings. That’s where this comes in.

I’ve curated specific shows that consistently deliver evidence-based insights you can actually use. Think less fluff, more substance. The kind of information that changes how you practice or how you live.

Got a podcast that’s been delivering gold? Send it my way. I’m always hunting for voices that push the field forward.

This Newsletter Is Sponsored By Casa de Sante.

The most consistent signal across this week’s episodes isn’t about hormones. It’s about muscle—and the clinician’s irreplaceable role in protecting it.

On Not Your Mother’s Menopause, Liz Baker Plosser laid out the biochemical reality with unusual clarity: estrogen loss doesn’t just accelerate muscle breakdown, it blunts the anabolic response to the protein you do eat. That’s anabolic resistance—and it means the menopausal patient who is “eating enough” is functionally eating less, at the cellular level. The fix isn’t complicated, but it requires a prescription: ≥100 g of protein daily, spread across meals, a leucine-enriched essential amino acid supplement as a daily “insurance policy,” and creatine monohydrate at 3–5 g/day (bump to 10 g after disrupted sleep for the cognitive uplift). The three work as a system—whole food protein as the foundation, EAAs as targeted signal, creatine as the cellular battery charger.

The GLP-1 episode on The Plus SideZ made the same argument from a different angle: the myth that semaglutide and tirzepatide eat muscle is not a pharmacology story—it’s a nutrition and training story. Lean mass loss is a protein deficit and sedentary lifestyle story wearing a drug’s name tag. The antidote is identical: ≥100 g protein, 10 minutes of resistance training three days a week (isometrics, resistance bands, bodyweight—nothing fancy), and body composition tracking every 8–12 weeks with bioimpedance. The strategic implication is direct: any clinician prescribing a GLP-1 RA without simultaneously issuing a “muscle-preservation bundle” is leaving the most important part of the prescription blank.

And from Menopause Mastery—the fracture conversation extended this logic to bone. DXA, it turns out, is a surprisingly blunt instrument: it identifies only ~44% of women with osteoporosis who will actually fracture, and in lower-risk patients under 70, predictive value can sink to ~5%. Falls cause ~95% of fractures. The 10-second one-leg-stand balance test—which costs nothing and takes 10 seconds—is more actionable at point-of-care than a T-score alone. Resistance and balance training, adequate protein (~0.6 g/lb/day), medication stewardship (SSRIs, PPIs, and glucocorticoids all increase fracture risk), and sleep optimization are the levers that actually move fracture outcomes. The message is this: stop treating the DXA number and start treating the falling body.

For anyone on GLP-1 medications like Ozempic or Wegovy, Low FODMAP nutrition is non-negotiable. These medications can slow digestion and trigger bloating or nausea, so choosing gut-friendly products helps you stay comfortable while protecting muscle and metabolism. Physician-formulated by Dr Onyx MD PhD Certified in Obesity Management, this Low FODMAP lineup supports nutrient absorption, muscle defense, and overall digestive balance:

• Premium Protein Powder (Vegan Vanilla, Whey Vanilla, or Whey Chocolate) – helps preserve lean muscle during weight loss

• FODMAP Digestive Enzymes – improves absorption and reduces GI side effects

• Advanced Probiotic + Prebiotic Synbiotic Formula – supports a balanced gut microbiome

• Essential Vitamin & Mineral Complex – replenishes nutrients often depleted during rapid weight loss

• Gentle Colon Cleanse + Probiotic Support – aids regular elimination without irritation

All formulas are low FODMAP, non-GMO, and third-party tested—the ideal foundation for GLP-1 users focused on digestive comfort, metabolic health, and muscle preservation.

Because hormones and skin health are deeply connected, Dr Onyx MD PhD science-backed skincare supports barrier repair, hydration, and inflammation balance for healthy, resilient skin—especially during menopause or while using GLP-1 medications, when collagen loss and dryness can accelerate:

• HydraLift Collagen Complex – firms and smooths for youthful elasticity

• Antioxidant C+E Ferulic Radiance Serum – brightens and defends against oxidative stress

• Needle-Free Wrinkle Smoother – softens fine lines without irritation

• Ultra Retinol 10x + Bakuchiol Serum – boosts cell turnover with gentle plant retinol

• Advanced Retinol Eye Repair – targets puffiness and under-eye wrinkles

• Cellular Repair Growth Factor Peptides Serum – rejuvenates and supports skin repair

• Advanced Neck Lift Firming Complex – improves tone and texture along the jawline and neck

• Even Tone Brightening Cream – evens discoloration for radiant, balanced skin

Three episodes this week converged on a damaging institutional failure: the systematic under-recognition of menopause as a diagnosable, treatable condition.

Susan Dominus, speaking on Hello Menopause!, articulated the structural problem with the precision of someone who spent a year reporting it: cultural bias labels menopausal symptoms as “just aging,” knowledge gaps mean clinicians across specialties miss the unifying diagnosis, and outdated WHI risk narratives continue to cast a long shadow over prescribing decisions. Her most actionable reframe: a symptom-focused, shared decision-making approach means that if a patient seeks help, that is the threshold for clinical significance—no hormone panel required to initiate a therapeutic conversation. Risk communication should use absolute numbers (the WHI showed a small absolute breast cancer risk increase with combined therapy; estrogen alone in women without a uterus may actually reduce breast cancer risk). A time-limited therapeutic trial of MHT does double duty: it relieves symptoms and helps attribute them to hormonal change.

Dr. Heather Hirsch’s episode on Health By Heather Hirsch adds critical operational context: the hormone therapy journey is not a one-and-done prescription. Roughly 80% of patients require an iterative titration process; only ~5% are immediate responders; and about 15% are highly sensitive and need a “start low, go slow” approach with close monitoring. The clinical error isn’t initiating MHT—it’s initiating it without a structured follow-up plan. Schedule a 4–6 week callback, adjust one variable at a time, and use a brief symptom diary. Paradoxical responses (progesterone worsening sleep, for instance) are real and require route or dose pivots, not discontinuation.

On All About You with Dr. Shauna Watts, the focus shifted to women years beyond menopause who have been told their brain fog, insomnia, weight redistribution, and joint pain are the price of getting older. The reframe is clinically significant: these are often manifestations of ongoing estrogen deficiency, not inevitable aging—and modern body-identical HRT (transdermal 17β-estradiol plus oral micronized progesterone) carries a meaningfully different and more favorable safety profile than the synthetic formulations that generated the 2002 WHI headlines. The emerging FSH science adds a layer: chronically elevated FSH post-menopause may independently correlate with osteoporosis, cardiovascular disease, and Alzheimer’s risk—a hypothesis that deserves clinical attention as the research matures. The practical directive: for any symptomatic postmenopausal patient, do a comprehensive baseline (CV risk, DEXA, thyroid, B12, vitamin D, current breast screening) and then have the individualized conversation—rather than preemptively closing the door.

The week’s most sophisticated clinical material centered on a single unifying idea: the tests and frameworks clinicians rely on most—standard lipid panels, DXA, routine urine cultures, PMDD diagnoses, and the 10-year ASCVD calculator—systematically underperform in midlife women. Precision requires a different toolkit.

On Hit Play Not Pause, dietitian Michelle Routhenstein dismantled the frustrating clinical scenario of the “doing everything right” patient whose labs are getting worse. The mechanism is estrogen loss: declining estrogen reduces LDL-receptor activity, drops nitric oxide bioavailability, alters the gut microbiome, and increases insulin resistance—meaning lab deterioration is a predictable, physiologic consequence of menopause, not a lifestyle failure. The standard lipid panel and 10-year calculator both miss women’s disease: microvascular pathology and soft plaque are invisible to coronary calcium scores, and Lp(a) elevation (present in ~30% of women) is entirely genetic and won’t respond to lifestyle. The advanced panel she recommends—ApoB, Lp(a), hsCRP, LP-PLA2 activity, LP-IR, A1c, omega-3 index, homocysteine—is the difference between a risk map and a risk sketch. And critically: underfueling and aggressive low-carbohydrate dieting—common midlife responses to weight gain—can paradoxically worsen lipid profiles and accelerate soft plaque progression.

The DUTCH Podcast applied the same precision-first logic to PMS and PMDD. The reframe is neurobiological: these are not conditions of hormone excess or deficiency, but of CNS sensitivity to normal hormonal fluctuations, amplified by HPA-axis dysregulation, glycemic instability, and circadian disruption. A mid-luteal, multi-system workup (estradiol, progesterone, DHEA, insulin/A1c, and a 4–5 point cortisol with cortisol awakening response) maps the actual drivers. First-line interventions—morning light, evening breathwork (the physiological sigh), post-meal walks, fiber, calcium, B6, magnesium, and Vitex—address root-cause physiology rather than masking symptoms. SSRIs and OCPs remain valid bridge tools within shared decision-making, but the sequence matters: circadian and metabolic stabilization first.

The Sky Women’s Health episode offered perhaps the week’s most underappreciated clinical pivot: women presenting with recurrent UTI-like symptoms and persistently negative cultures may not have a urologic problem at all. In a 2016 retrospective review, 85% of such patients had hormonally mediated vestibulodynia (HMV) with pelvic floor hypertonicity—and 98.9% had low free testosterone, making this a pre- and perimenopausal issue, not just a postmenopausal one. The vestibule, urethra, and bladder trigone share embryologic origin and are all estrogen- and androgen-receptor dense. Hormone deficiency initiates a cascade: vestibular inflammation → microbiome disruption → pelvic floor guarding → bladder irritability. Antibiotics don’t interrupt this cascade. Local vaginal estrogen (or intravaginal DHEA/prasterone), plus compounded low-dose estradiol/testosterone gel for vestibular tissue, plus pelvic floor physical therapy—that’s the protocol that addresses the actual pathology. The strategic takeaway for any busy practice: add a Q-tip vestibular mapping exam and pelvic floor tone assessment to the evaluation of every “recurrent UTI” patient with negative cultures, and stop the antibiotic reflex.

And finally, Dr. Felice Gersh on The Girlfriend Doctor made the case that progesterone is a whole-body hormone, not an endometrial afterthought—with neuroprotective, cardiometabolic, immune-modulating, and musculoskeletal functions that warrant consideration even in women without a uterus. Her argument for cyclic, physiologic bioidentical progesterone (vaginal or rectal routes, 12–14 days per 28-day cycle) over continuous nightly oral dosing targets a real pharmacokinetic problem: oral micronized progesterone’s first-pass metabolism generates supraphysiologic allopregnanolone, which may be useful acutely for sleep but is potentially excessive chronically. The OvaryActive episode on MHT and cardiovascular disease adds the necessary counterweight: transdermal 17β-estradiol avoids first-pass hepatic metabolism, minimizes clotting factor activation, and carries a more favorable stroke risk profile than oral estradiol—but MHT should not be initiated for primary CVD prevention, full stop. The evidence for modern regimens as cardioprotective is intriguing but insufficiently robust. Use MHT for symptom relief and bone protection; use proven CVD risk-reduction strategies for the heart.

URL: Listen Here

This episode clarifies how protein, essential amino acids, and creatine differ and work together to support muscle, recovery, energy, and cognition in midlife women. It emphasizes practical intake targets, third-party-tested leucine-enriched EAAs as a daily ‘insurance policy,’ and creatine’s performance and potential cognitive benefits—including after poor sleep. The discussion is evidence-aware but cites few formal references; apply recommendations individually and in clinical context.

• Midlife women commonly under-consume protein, and age- and estrogen-related anabolic resistance makes adequate intake more important—not less—targeting ≥100 g/day or ~1 g/lb ideal body weight, spread across meals.

• Essential amino acids (EAAs)—especially leucine-enriched formulations—directly drive muscle protein synthesis and support recovery, energy, mood, and overall cellular function; third-party testing and labeled EAA amounts matter.

• Creatine monohydrate boosts cellular ATP availability and intracellular hydration, improving training performance and potentially cognition/alertness, including after poor or fragmented sleep; daily timing is flexible as stores saturate over time.

• Protein powders (e.g., whey as a complete protein) are dietary tools to help reach meal targets; pairing whole-food protein with daily EAAs can reduce stress around consistently hitting high protein numbers.

• There is a persistent menopause-care gap; clinicians should proactively address protein intake, EAA and creatine use, and progressive resistance training to mitigate sarcopenia and enhance quality of life in perimenopause/menopause.

Leucine-enriched essential amino acid supplementation, paired with creatine monohydrate, can help offset menopause-related anabolic resistance and reduced mitochondrial efficiency—supporting preservation/building of lean mass, recovery, and function even when appetite declines and sleep is disrupted.

For a typical perimenopausal/menopausal patient without contraindications, set a protein goal ≥100 g/day (~30 g/meal), add a daily third-party-tested leucine-enriched EAA supplement and creatine monohydrate 3–5 g/day (consider 10 g on days after poor sleep or high cognitive load), and pair with progressive resistance training 2–3 times/week; monitor tolerance and renal function as clinically indicated.

URL: Listen Here

This episode reframes PMS/PMDD as conditions driven largely by CNS sensitivity to normal hormone fluctuations, magnified by stress physiology and metabolic factors. It outlines a practical, root-cause protocol—timed functional testing, circadian and nervous-system interventions, blood sugar strategies, and select nutraceuticals—while acknowledging that SSRIs or OCPs may be appropriate bridge tools within shared decision-making.

• PMS and PMDD share similar symptoms, but PMDD is defined by functional impairment and a distinctly cyclic pattern that worsens after ovulation and remits within 1–2 days of menses; baseline anxiety may coexist but does not fully account for PMDD.

• Most PMS/PMDD cases reflect heightened CNS sensitivity to normal hormonal fluctuations—not frank hormone imbalance; estrogen supports serotonin signaling, while progesterone’s metabolite allopregnanolone modulates GABA, and HPA-axis stress reactivity and blood sugar dysregulation amplify symptoms in the luteal phase.

• A functional workup should be time-specific (mid-luteal) and multi-system: estradiol/progesterone, DHEA, insulin/A1C/glucose, and multi-point cortisol with CAR; DUTCH testing can add diurnal cortisol patterns, cycle mapping, and progesterone metabolite ratios (alpha/beta) relevant to GABAergic effects.

• First-line care emphasizes circadian and nervous-system regulation (sleep hygiene, morning/evening light, breathwork such as the physiological sigh), plus blood sugar support (fiber and post-meal walks); evidence-supported nutraceuticals include calcium, vitamin B6, zinc, magnesium, vitamin D, L-theanine, chaste tree (Vitex), lavender oil (Silexan), and curcumin.

• Progesterone is not a universal solution for PMS/PMDD; individualized, shared decision-making may include SSRIs or combined oral contraceptives as effective bridge therapies while root-cause drivers (stress, sleep, metabolic health, gut/liver processing) are addressed.

PMS/PMDD primarily reflect neurobiological sensitivity to normal hormonal shifts; addressing HPA-axis dysregulation, sleep/circadian rhythm, and glycemic control often improves symptoms more reliably than attempting to ‘fix’ hormone levels alone.

Schedule a mid-luteal, multi-system assessment (estradiol, progesterone, DHEA, insulin/A1C/glucose, and a 4–5 point cortisol with CAR), and use the results to target nervous-system support and glycemic control before considering hormone therapy.

URL: Listen Here

Journalist Susan Dominus discusses the menopause information gap, how cultural bias and fragmented care contribute to under-treatment, and why clinicians should pivot to symptom-oriented, shared decision-making. The conversation reviews WHI findings, clarifies risk communication, and highlights practical steps—like screening for menopausal status and considering a therapeutic trial of MHT—to improve care and patient agency.

• Menopause care is hampered by cultural bias and a knowledge-translation gap; many clinicians minimize symptoms as “just aging,” leaving patients without guidance or treatment.

• Clinicians should define “significant” symptoms through a patient-centered lens; if a patient seeks help, that alone signals clinical significance, and perimenopausal symptoms can be treated without routine hormone panels.

• Risk communication about menopausal hormone therapy (MHT) should use clear absolute risks (natural frequencies) and shared decision-making; WHI data showed small absolute breast cancer risk increases with combined therapy, while estrogen-alone did not increase—and may reduce—breast cancer risk in women without a uterus.

• A short, supervised therapeutic trial of MHT can both relieve symptoms (e.g., vasomotor symptoms, sleep disruption, joint pain, dry eyes/mouth) and help attribute them to hormonal changes; discontinue if ineffective.

• System fragmentation leads many specialties to miss menopause as a unifying diagnosis; routinely screening midlife women for menopausal status and empowering patient agency can prevent misdiagnosis, delays, and unnecessary workups.

Adopt a symptom-focused, shared decision-making approach to perimenopause/menopause that normalizes treatment when symptoms are bothersome, avoids dismissing them as aging, and frames MHT risks in absolute terms while routinely screening midlife women for menopausal status across all specialties.

At visits with women aged ~45–55, ask about menstrual status and menopausal symptoms; when symptoms are bothersome and no contraindications exist, discuss absolute risks/benefits and consider a time-limited therapeutic trial of MHT (without ordering routine hormone panels).

URL: Listen Here

This episode debunks common myths about GLP-1 medications—especially the claim that they cause muscle loss—by emphasizing protein intake, brief resistance training, and body-composition tracking. The clinicians explain insulin and leptin resistance, outline the phased nature of weight loss (including expected plateaus/regain), and highlight practical ways to enhance metabolic health and quality of life while using GLP-1 RAs. The discussion underscores careful dose titration, stigma reduction, and long-term maintenance planning as essential to modern obesity care.

• GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) do not inherently ‘eat’ muscle; lean mass loss accompanies any weight loss when protein intake and resistance training are inadequate. A simple, effective safeguard is ~100 g/day of protein plus brief resistance training (e.g., 10 minutes, 3 days/week), with body-composition monitoring.

• Effective strength training can be minimal and equipment-free (isometrics, bodyweight, resistance bands, kettlebells). Many patients can maintain or even gain muscle during GLP-1 therapy when protein targets and brief, consistent training are met.

• Endogenous GLP-1 can be modestly boosted by bitter vegetables (e.g., Brussels sprouts, broccoli, cabbage), regular exercise, hydration, dietary protein, stress reduction, and sleep; certain supplements (e.g., berberine, allulose, cinnamon) were mentioned. However, native GLP-1 has a ~2-minute half-life (rapidly degraded by DPP-4), so these effects are transient and often insufficient to treat obesity alone.

• Weight loss typically follows phases: Phase 1 (rapid water/glycogen loss), Phase 2 (slow, true fat loss—often ~0.5 lb/week), and a set-point phase with possible partial regain (up to ~20% of lost weight) before further loss. Similar patterns occur after bariatric surgery (often faster due to larger caloric deficits). Normalize plateaus and small regains.

• Obesity is a chronic, highly genetic metabolic disease (language and stigma matter). Only a small fraction of eligible patients receive anti-obesity medications. Clinicians should titrate GLP-1 RAs slowly per labeling, pair treatment with nutrition/exercise/behavioral support, and plan for maintenance that requires ongoing adaptation; many patients prefer continuing therapy for sustained quality-of-life benefits (e.g., reduced food noise).

The primary clinical imperative is not to attribute sarcopenia to GLP-1 RAs but to proactively preserve lean mass by coupling pharmacotherapy with a structured protein target and minimal, sustainable resistance training, while setting expectations for phased weight loss and normalizing small regains.

When initiating a GLP-1 RA, create a ‘muscle-preservation bundle’: set a protein goal (e.g., ≥100 g/day or ~1.2–1.6 g/kg ideal body weight), prescribe a simple resistance plan (10 minutes, 3 days/week of isometrics/bodyweight/bands/kettlebells), titrate the medication slowly per label, and track body composition (e.g., bioimpedance) every 8–12 weeks.

URL: Listen Here

This episode explains why cardiometabolic labs often worsen in perimenopause/menopause and how to interpret and intervene beyond standard lipid panels and risk calculators. It emphasizes advanced testing, the role of gut and nitric oxide biology, and a nutrition strategy centered on adequate fueling, complex carbohydrates, fiber diversity, and fermented foods—paired with personalized decisions about medications such as statins.

• Menopausal estrogen decline reduces LDL-receptor activity and nitric oxide bioavailability, alters the gut microbiome, and increases insulin resistance—driving rises in LDL/ApoB, Lp(a) (in ~30% of women), blood pressure, and A1c despite unchanged lifestyle.

• Traditional 10-year risk calculators and coronary calcium scores can miss women’s disease (microvascular disease and soft plaque). Advanced labs (ApoB, Lp(a), hsCRP, LP-PLA2 activity, LDL particle data, LP-IR) and, when available, CCTA with Cleerly provide a clearer risk picture.

• Underfueling and low-carbohydrate dieting—common responses to midlife weight and lab changes—can worsen lipid and glycemic profiles, increase soft-plaque progression, and impair performance; adequate complex carbohydrates, soluble/insoluble fiber, and fermented foods are protective.

• Gut health is pivotal: excessive animal-source choline/carnitine can raise TMAO and arterial stiffness; prioritize fiber diversity and fermented foods (3–5 servings/week), assess symptoms (Bristol stool chart), and correct dysbiosis to support vascular and nitric oxide pathways.

• Statins can be beneficial and necessary for some, but therapy should be individualized; many women improve ApoB/LDL and inflammatory markers with targeted nutrition and lifestyle. Even on medication, diet and lifestyle remain essential.

For midlife women, relying on LDL-C and 10-year risk alone is insufficient. Clinicians should account for menopause-related pathophysiology (microvascular disease, estrogen loss) and use advanced risk markers—ApoB, Lp(a), hsCRP, LP-PLA2 activity, LP-IR—and consider imaging that detects soft plaque to more accurately stratify risk and guide individualized therapy.

For an active perimenopausal patient with ‘worsening’ labs, order a targeted panel (ApoB, Lp(a), non-HDL-C or LDL-P, hsCRP, LP-PLA2 activity, LP-IR, A1c, vitamin D, omega-3 index, iron panel, homocysteine), monitor blood pressure closely, and counsel to increase complex carbohydrates and soluble fiber to 25–30 g/day plus 3–5 fermented-food servings/week and nitrate-rich vegetables (e.g., beets, leafy greens), while reducing excess saturated fat, high-sodium electrolyte powders, and frequent red meat; reassess in ~3 months and personalize from results.

URL: Listen Here

This episode explains how to recognize and manage depression and anxiety during pregnancy, emphasizing functional red flags, routine screening, and integrated OB–psychiatry care. It outlines individualized, evidence-informed decisions about antidepressant use, the risks of untreated illness, and reliable resources to guide safe, patient-centered treatment.

• Perinatal depression and anxiety commonly begin in pregnancy; routine screening and strong collaboration between OB/GYNs, psychiatrists, primary care, and support services are critical, yet training gaps still lead to missed or undertreated cases.

• Differentiate normal pregnancy worry from a disorder by assessing functional impairment (sleep, appetite, self-care, relationships), excessive time spent seeking information online, isolation, and diminished capacity for joy or bonding—these are red flags warranting evaluation.

• Medication decisions must be individualized: for many patients, continuing an effective antidepressant (e.g., SSRIs, bupropion) in pregnancy is reasonable; treat to wellness before delivery and pair pharmacotherapy with psychotherapy, exercise, nutrition, and social support.

• Untreated maternal depression/anxiety increases risk for adverse maternal–infant outcomes and can affect bonding and child development; preconception planning helps optimize a pregnancy-compatible, effective regimen and reduces relapse risk.

• Current evidence does not support antidepressants as a causal factor for miscarriage after accounting for underlying illness; trusted, up-to-date resources include MotherToBaby, the MGH Center for Women’s Mental Health (and its National Pregnancy Registry), and Postpartum Support International.

Risk–benefit counseling in pregnancy must explicitly weigh the harms of untreated mood/anxiety disorders; for many patients, maintaining a known effective antidepressant and aiming for remission by delivery—within a multimodal care plan—best supports maternal and infant outcomes.

At the preconception or first prenatal visit, perform a structured mental health assessment and medication review, discuss individualized risks/benefits of continuing current therapy, and provide written referrals to MotherToBaby (medication safety counseling) and Postpartum Support International/MGH Women’s Mental Health for ongoing support and follow-up.

URL: Listen Here

This episode challenges the reliance on DXA as a ‘gold standard’ for fracture prediction and emphasizes that most fracture risk stems from falls and modifiable clinical factors—especially medications, balance, nutrition, and sleep. The guests outline a comprehensive, integrative approach: earlier and smarter screening (including Z-scores and judicious use of bone turnover markers for monitoring), medication review, strength/balance training, adequate protein, and sleep health. Note: Several statistics were cited without specific study names in the discussion.

• DXA bone mineral density (BMD) alone is a poor predictor of fractures: it identifies only ~44% of women (and ~21% of men) with osteoporosis who will fracture; in adults <70 with low fall risk, predictive value can drop to ~5%. Use Z-scores (not T-scores) for premenopausal women.

• Falls drive ~95% of fractures—assess and improve fall risk factors such as balance (10-second one-leg-stand), gait speed, grip strength, foot health, and sleep; sleep loss elevates cortisol, worsens balance, and accelerates bone loss.

• Common medications increase fracture and/or fall risk (SSRIs/SNRIs, PPIs, prednisone, anti-seizure drugs, and often long-term antihypertensives without dose review); polypharmacy and lack of periodic medication reviews compound risk.

• Screening is underutilized: many at-risk women are not tested before a fracture. Consider a baseline DXA around age 50 (and after any fracture at ≥50), interpret results alongside FRAX and clinical factors rather than treating the DXA number alone.

• Lifestyle remains central: ensure adequate protein intake (~0.6 g/lb/day) and prioritize resistance/strength and balance training—muscle and bone gains are achievable even in older adults; watch for GLP-1–associated undernutrition that can indirectly harm bone.

Fracture prevention should prioritize fall-risk mitigation, medication stewardship, and targeted lifestyle interventions (protein intake, resistance/balance training, sleep optimization) rather than relying on DXA numbers alone.

Add a 10-second one-leg-stand balance test to routine visits for women ≥50; if patients cannot hold for 10 seconds, initiate a fall-prevention plan (referral for strength/balance training, review of fall-risk medications, home safety and sleep optimization) and reassess.

URL: Listen Here

This episode reframes progesterone as a whole‑body hormone whose cyclic, physiologic replacement can enhance neuro, immune, cardiovascular, and musculoskeletal health in menopause. The guests advocate individualized, route‑ and dose‑conscious prescribing (often vaginal/rectal) and careful monitoring, including in complex contexts such as long‑standing menopause and breast cancer survivorship. Note: several mechanistic claims draw on preclinical or legacy data, and high‑quality trials directly comparing cyclic versus continuous regimens in menopausal women remain limited.

• Progesterone is a multi‑system “life hormone,” not just an endometrial protector; it has important neuroprotective, cardiometabolic, immune‑modulating, and musculoskeletal effects and merits consideration even in women without a uterus.

• Cyclic, physiologic replacement of bioidentical progesterone (to mimic a luteal phase) is favored over continuous daily oral dosing; vaginal or rectal routes reliably achieve systemic levels and provide endometrial protection with fewer supraphysiologic allopregnanolone effects.

• Oral micronized progesterone undergoes extensive first‑pass metabolism, generating high allopregnanolone that can aid sleep/anxiety acutely but may be excessive chronically; delivery route and dose should be individualized and monitored.

• HRT should be personalized by time since menopause and overall health: start slower and address inflammation, gut microbiome, and cardiometabolic risks in women many years postmenopause; recent menopausal patients can often begin at optimal doses.

• Any postmenopausal bleeding requires standard GYN evaluation (e.g., pelvic ultrasound, cervical assessment), although predictable, timed withdrawal bleeding on cyclic therapy alone is not a cancer signal.

For postmenopausal hormone therapy, bioidentical progesterone used cyclically at physiologic (luteal‑like) levels—preferably via vaginal or rectal routes—may better support brain and whole‑body health and protect the endometrium than continuous nightly oral dosing that drives supraphysiologic allopregnanolone.

In a symptomatic postmenopausal woman with a uterus starting HRT, consider transdermal estradiol plus cyclic vaginal micronized progesterone 200–300 mg nightly for 12–14 days each 28‑day cycle; document a bleeding calendar, monitor levels and symptoms, and perform pelvic ultrasound if bleeding is atypical or unscheduled.

URL: Listen Here

This episode reviews what MHT can and cannot do for cardiovascular prevention. Evidence from WHI and subsequent studies indicates that starting older oral regimens long after menopause increases CVD risk, while limited modern data suggest neutral to modestly favorable profiles when therapy is started near menopause—yet not enough to justify MHT as primary CVD prevention. Clinicians should individualize MHT for symptom and bone benefits, prefer routes that minimize coagulation effects, and rely on proven CVD prevention strategies.

• Observational cohorts (Framingham, Nurses’ Health Study) identified rising cardiovascular disease (CVD) risk after menopause and generated hypotheses about cardioprotection from menopausal hormone therapy (MHT), but these designs are confounded and cannot prove benefit.

• The Women’s Health Initiative (WHI) found that initiating oral conjugated equine estrogens ± medroxyprogesterone acetate in older women long after menopause increased CVD risk; age/timing subanalyses informed the “timing hypothesis,” suggesting earlier initiation carries less risk and possible benefit with estrogen alone.

• High-quality randomized data for today’s common regimens (17β-estradiol, especially transdermal, and micronized progesterone) are limited; one randomized trial starting near menopause (DOPS) showed fewer CVD events with oral estradiol, while large registry/claims studies suggest similar MI risk for oral vs transdermal and possibly lower stroke risk with transdermal, but these are observational and prone to bias.

• Route of estrogen delivery matters physiologically: oral estradiol undergoes first-pass hepatic metabolism, increasing clotting factors and altering lipids; transdermal estradiol minimizes hepatic coagulation effects and has more neutral lipid effects.

• Bottom line: Do not use MHT for primary CVD prevention. Use MHT for symptom relief and bone health when indicated, individualize route/dose (often favoring transdermal for risk optimization), and prioritize proven CVD risk-reduction strategies (lifestyle, risk-factor control, statins when indicated).

Menopausal hormone therapy should not be prescribed for primary prevention of cardiovascular disease; if MHT is indicated for symptom control, initiate near the menopausal transition when appropriate and consider transdermal estradiol to minimize thrombotic and stroke-related risks, while addressing CVD prevention through evidence-based lifestyle and medical therapies.

At perimenopause, perform a formal ASCVD risk assessment and optimize modifiable risks (exercise, nutrition, BP, lipids, diabetes); if prescribing MHT for symptoms in an otherwise low-risk woman close to menopause, discuss route trade-offs and consider transdermal 17β-estradiol (with micronized progesterone if uterus intact), avoiding initiation for CVD prevention and avoiding new starts ≥60 years or >10 years after menopause.

URL: Listen Here

This episode outlines three common hormone therapy trajectories—titrators, immediate responders, and highly sensitive patients—emphasizing that most women require iterative adjustments over time. It highlights a symptom-prioritized, evidence-based approach with close follow-up, flexibility across formulations, and consideration of underlying sensitivities to optimize outcomes in peri- and postmenopause.

• Most women experience a titration-focused hormone therapy journey (~80%), a smaller group are immediate responders (~5%), and ~15% are highly sensitive to hormones and require very low-and-slow adjustments.

• Begin management by identifying and targeting the single most bothersome symptom (e.g., insomnia, genitourinary syndrome of menopause) and expect iterative tweaks; the first regimen may not be perfect even with expert care.

• Responses to estrogen, progesterone, and (when appropriate) testosterone are highly individualized; paradoxical reactions (e.g., progesterone worsening sleep) occur and may require route or dose changes.

• External factors—stage of peri/menopause, life stress, comorbidities, pharmacy shortages/insurance changes—frequently necessitate regimen adjustments or alternative formulations (patch, gel, spray, ring, oral, injectables).

• Close, longitudinal follow-up (every 4–6 weeks early on, then every 6 months once stable) and an evidence-based, FDA-approved approach improve outcomes; consider underlying conditions (e.g., mast cell activation syndrome, progesterone allergy) in ultra-sensitive patients.

Menopausal hormone therapy is a longitudinal, symptom-driven, and highly individualized process; clinicians should normalize the need for ongoing titration and plan structured follow-up to adjust dose, route, and agents based on patient-reported outcomes.

At initiation, identify the patient’s single most bothersome symptom, start with the simplest evidence-based regimen addressing it, and schedule a 4–6 week follow-up to adjust one variable at a time (dose or route), using a brief symptom diary—start ultra-sensitive patients at very low doses and go slow.

URL: Listen Here

This episode reviews how to choose and use sunscreens effectively for summer 2026, emphasizing daily, broad-spectrum SPF ≥30, tailoring by skin type/tone/activity, and practical product formats (mineral/tinted, water-resistant, sticks/sprays) to boost adherence. It highlights the U.S. lag in UV filter approvals yet underscores that current options can deliver excellent protection, with sunscreen serving as a high-ROI intervention against photoaging and skin cancer; vitamin D levels generally are not compromised by regular use. Limitation: the episode references supporting evidence broadly without citing specific studies by name.

• Daily, broad-spectrum sunscreen (SPF ≥30) is a non-negotiable cornerstone of skin health; UVA penetrates glass, most people under-apply, and slightly higher SPFs help offset under-application.

• Adherence hinges on cosmetic elegance and fit—choose formulations by skin type, tone, and activity; makeup or powder alone is insufficient for primary protection.

• Mineral sunscreens (zinc/titanium) are preferred for sensitive skin, post-procedure care, and melasma; tinted/iron oxide-containing options improve blend on darker skin tones and help block visible light.

• On high UV/sweaty days, prioritize water-resistant “sport” formulas that won’t sting eyes; sticks and sprays can improve use in kids but should be rubbed in.

• While U.S. UV filter innovation has lagged behind Europe/Asia (no OTC approvals since 1999, with a new UVA filter anticipated), excellent options exist domestically; sunscreen remains a cost-effective strategy to prevent photoaging and skin cancer, and typical use does not meaningfully reduce vitamin D levels.

The most impactful clinical point is that consistent daily use of a broad-spectrum SPF ≥30 tailored to the patient’s skin type, tone, and lifestyle (e.g., mineral/tinted for melasma or sensitive skin; water-resistant for high UV or sweat) maximizes adherence and meaningfully reduces photoaging and skin cancer risk—even during routine indoor exposure near windows.

Write a “sunscreen prescription” at visits: advise patients to apply a broad-spectrum SPF ≥30 every morning to all exposed skin, select a cosmetically elegant formula they like (mineral/tinted for melasma or sensitive/post-procedure skin), and plan reapplication during outdoor or sweaty activities with a water-resistant product kept in the car/bag.

URL: Listen Here

This episode reframes recurrent, culture-negative UTI symptoms as a potential manifestation of hormone deficiency affecting a unified vestibule–urethra–bladder system, aligning hormonally mediated vestibulodynia with GSM. It outlines a practical shift toward pelvic/vestibular examination, pelvic floor therapy, and local estrogen ± androgen therapy, while emphasizing that current evidence is primarily retrospective and warrants prospective trials.

• In women with recurrent UTI-like symptoms and persistently negative urine cultures, the predominant driver may be hormonally mediated vestibulodynia (HMV) with pelvic floor hypertonicity—85% had HMV findings and only 15% had classic urologic causes in a 2016 retrospective review.

• The vulvar vestibule, urethra, and bladder trigone share embryologic origin and dense estrogen/androgen receptor expression; hormone deficiency (estrogen and/or androgens) can therefore produce bladder/urethral symptoms that mimic UTIs, uniting HMV and GSM as the same pathophysiologic process across the lifespan.

• Androgen deficiency appears central: among pre- and perimenopausal patients tested, 98.9% had low free testosterone, indicating this is not solely a postmenopausal condition.

• A proposed cascade explains persistent symptoms: hormone deficiency → vestibular inflammation and microbiome shift → pelvic floor guarding (hypertonicity) → urethral/bladder irritability and dysfunctional voiding; antibiotics do not correct the hormonal driver.

• Clinical management should shift from reflexive antibiotics to comprehensive pelvic/vestibular exam, pelvic floor physical therapy, and local hormone therapy (vaginal estrogen or intravaginal DHEA; consider adding topical vestibular estradiol plus testosterone for androgen-dominant vestibular tissue), while acknowledging the evidence is preliminary and based on retrospective, specialty-clinic data.

For women with recurrent urinary urgency, frequency, or dysuria and negative cultures, clinicians should prioritize evaluation for hormonally mediated vestibulodynia/GSM and pelvic floor hypertonicity—reflecting a hormone-responsive urogenital unit—rather than repeatedly treating presumed infection; targeted local estrogen ± androgen therapy and pelvic floor physical therapy can address the underlying pathology.

In patients with persistent UTI-like symptoms and negative cultures, obtain a pre-antibiotic urine sample and perform a focused pelvic exam (including Q‑tip vestibular mapping and pelvic floor tone assessment); if findings suggest GSM/vestibulodynia, initiate local therapy (e.g., vaginal estradiol or intravaginal prasterone) and, for vestibular pain, consider adding a compounded low-dose estradiol 0.01% + testosterone 0.1% gel applied to the introitus, alongside referral to pelvic floor physical therapy, with reassessment in 8–12 weeks.

URL: Listen Here

This episode reframes common postmenopausal complaints as manifestations of estrogen deficiency with treatable causes, not inevitable aging. It corrects misconceptions from earlier HRT research, underscores the safety and benefits of body-identical regimens, and outlines a practical, individualized workup and management plan for women many years past menopause.

• Persistent postmenopausal symptoms (brain fog, sleep disruption, weight redistribution, genitourinary symptoms, bone loss) are often due to ongoing estrogen deficiency rather than “just aging.”

• Modern, body-identical HRT (transdermal 17β-estradiol with oral micronized progesterone when a uterus is present) has a different and generally more favorable safety profile than the synthetic regimens highlighted in early 2000s headlines.

• FSH remains chronically elevated after menopause as the brain continues to signal for estrogen; elevated FSH may be independently associated with osteoporosis, cardiovascular disease, obesity, and Alzheimer’s disease.

• Before initiating therapy in women many years post-menopause, undertake individualized assessment: cardiovascular risk evaluation, blood pressure, lipids, glycemia, bone density (DEXA), key labs (thyroid, iron, B12, vitamin D), and ensure up-to-date breast screening.

• Treatment options include systemic HRT, low-dose vaginal estrogen (minimal systemic risk) for urogenital symptoms, consideration of testosterone for select women, and non-hormonal alternatives when HRT is unsuitable.

For women well beyond their final period who have persistent symptoms or health risks, clinicians should reconsider attributing issues to aging alone and proactively evaluate for estrogen deficiency, offering individualized, evidence-based discussions about modern HRT alongside alternative options.

For a symptomatic postmenopausal patient (years after menopause), perform a comprehensive baseline evaluation—CV risk assessment (BP, lipids, glucose/HbA1c, family history), DEXA scan, thyroid/iron/B12/vitamin D, and ensure current breast screening—then use shared decision-making to consider a trial of transdermal 17β-estradiol with oral micronized progesterone (if uterus present), adding vaginal estrogen for GSM as needed.

URL: Listen Here

This episode details the prognosis of epithelial ovarian cancer, emphasizing late‑stage diagnosis, dependence of outcomes on residual disease after cytoreduction, and the near‑inevitability of early recurrence that shapes subsequent therapy and survival. It underscores the need for precise language, structured surveillance, and shared decision‑making to balance aggressive therapy against significant morbidity and quality‑of‑life considerations.

• Most epithelial ovarian cancers present at advanced stage (≈80% at stage III/IV), making a good prognosis unlikely; reported 5‑year survival is ~25% for stage III and ~15% for stage IV.

• Initial management typically involves primary cytoreductive (debulking) surgery followed by chemotherapy for stages I–III, while stage IV is often treated with chemotherapy alone; prognosis hinges on residual disease (complete resection vs optimal or suboptimal cytoreduction).

• Terminology such as “response” and “disease‑free period” reflects reduction rather than cure; clear surgical margins are not generally expected, and recurrence is the norm rather than the exception.

• Recurrence commonly occurs within about 4–6 months after initial therapy; classification as platinum‑sensitive (>6 months) or platinum‑insensitive (<6 months) guides retreatment, which may include secondary cytoreduction and additional chemotherapy but yields shorter disease‑free intervals (~3 months).

• Treatment morbidity is substantial (extensive surgery and toxic chemotherapy), so clinicians should emphasize realistic counseling, shared decision‑making, and surveillance using biomarkers (e.g., CA‑125, HE4, others) plus imaging, with early consideration of palliative approaches.

Because advanced presentation and rapid, expected recurrence drive outcomes, the volume of residual disease after initial cytoreduction and early, frank counseling about short disease‑free intervals are critical to guide surveillance intensity, retreatment choices (platinum sensitivity), and timely goals‑of‑care discussions that prioritize quality of life.

At the first post‑treatment follow‑up, set expectations about likely recurrence within months and establish a surveillance plan (e.g., every 3 months in year 1 with CA‑125 ± HE4 based on the patient’s baseline biomarkers and symptom review, using imaging as indicated), while initiating a documented goals‑of‑care discussion including palliative options.

Stay connected with Dr Onyx MD PhD for clinical insights and wellness tools that bridge science and everyday care:

Instagram ✦ X (Twitter) ✦ LinkedIn ✦ Website

Knowledge without execution changes nothing. The insights above only reach their full potential when integrated into a strategic, personalized plan. That’s where two offerings come in:

Healthcare complexity is overwhelming. Clinical studies, conflicting guidelines, and fragmented records leave most patients paralyzed.

Deploy your Dr Onyx MD PhD Medical AI Chatbot—a personalized architecture that synthesizes your medical history, the latest research, and your unique condition into clear, actionable insights.

It’s not a replacement for your doctors—it’s your secret weapon for making better decisions and becoming the CEO of your own care.

👉 Deploy your Medical AI Chatbot today and take control of your health narrative

Managing menopause isn’t about “getting through it”—it’s about doing it strategically. The Menopause Premium Program is a 16-week, high-touch protocol designed for high-performing women who demand more than quick fixes. With board-certified specialists, evidence-based hormone and non-hormonal options, and proactive risk reduction, this program helps restore clarity, stabilize sleep, and safeguard long-term health. If brain fog, disrupted nights, or unpredictable weight shifts are holding you back, this is your opportunity to take control with the same precision you bring to your career.

👉Discover the Menopause Premium Program